Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Quent Capital LLC

Quent Capital LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 42.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,717 shares of the biopharmaceutical company’s stock after purchasing an additional 811 shares during the period. Quent Capital LLC’s holdings in Gilead Sciences were worth $251,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in GILD. HHM Wealth Advisors LLC increased its position in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of Gilead Sciences in the third quarter worth approximately $25,000. YANKCOM Partnership purchased a new position in shares of Gilead Sciences in the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the fourth quarter worth approximately $29,000. Finally, Valued Wealth Advisors LLC increased its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $103.31 on Thursday. The firm has a fifty day simple moving average of $93.14 and a 200-day simple moving average of $87.12. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $104.71. The stock has a market capitalization of $128.75 billion, a price-to-earnings ratio of 1,147.89, a PEG ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 3.06%. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock valued at $53,611,715 in the last 90 days. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday. Piper Sandler boosted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Finally, Mizuho boosted their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $101.04.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.